Gossamer Bio, Inc.
GOSSAs of the close on Sep 25, 2026
Price
$10.94
Market cap
—
The cover-page share count does not match the latest report's share count
P/E (diluted TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
EPS (TTM)
—
The fourth quarter's per-share figure could not be confirmed from the annual report
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Gossamer Bio, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 9 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 5, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| ARCH Venture Management, LLC | 2026-03-31 | 8,055,916 | Not shown | SEC filing |
| Quarry LP | 2026-03-31 | 100,000 | Not shown | SEC filing |
| Orion Porfolio Solutions, LLC | 2026-03-31 | 15,220 | Not shown | SEC filing |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 2026-03-31 | 91,418 | Not shown | SEC filing |
| Farther Finance Advisors, LLC | 2026-03-31 | 3,674 | Not shown | SEC filing |
| AXQ CAPITAL, LP | 2026-03-31 | 20,421 | Not shown | SEC filing |
| Qube Research & Technologies Ltd | 2026-03-31 | 4,917,763 | Not shown | SEC filing |
| SMITH, MOORE & CO. | 2026-03-31 | 470,000 | Not shown | SEC filing |
| Evernest Financial Advisors, LLC | 2026-03-31 | 28,769 | Not shown | SEC filing |
| VOYA INVESTMENT MANAGEMENT LLC | 2026-03-31 | 866,615 | Not shown | SEC filing |
| MML INVESTORS SERVICES, LLC | 2026-03-31 | 10,000 | Not shown | SEC filing |
| Bull Harbor Capital LLC | 2026-03-31 | 31,196 | Not shown | SEC filing |
| Rothschild Wealth LLC | 2026-03-31 | 12,862 | Not shown | SEC filing |
| LPL Financial LLC | 2026-03-31 | 371,734 | Not shown | SEC filing |
| Siren, L.L.C. | 2026-03-31 | 5,208,968 | Not shown | SEC filing |
| Pallas Capital Advisors LLC | 2026-03-31 | 10,367 | Not shown | SEC filing |
| AlphaCore Capital LLC | 2026-03-31 | 53,011 | Not shown | SEC filing |
| Vanguard Personalized Indexing Management, LLC | 2026-03-31 | 17,531 | Not shown | SEC filing |
| NISA INVESTMENT ADVISORS, LLC | 2026-03-31 | 1,883 | Not shown | SEC filing |
- Each value is checked against Gossamer Bio, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 19 rows: no share price from within three months of their report dates is on file, so they could not be checked.
- 1 row left out: the value per share it reports is far from Gossamer Bio, Inc.'s share prices on file from around the report date, far from the value most filers reported for that date, or the value of a security already left out, so it may describe another security or share class.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Gossamer Bio, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2024-06-21 · Hasnain Faheem: Larger than 11 of the 12 other insider purchases of Common Stock on file. SEC filing
- 2023-03-22 · Hasnain Faheem: Larger than all 12 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2024-06-17–2024-06-21: 3 event(s) across 3 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing )
- 2023-11-13–2023-11-15: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2023-03-20–2023-03-22: 5 event(s) across 3 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-08-19 | Milligan Sandra · Director | Common Stock | P — Open market or private purchase | +26,050 | 1.92 | SEC filing |
| 2024-06-24 | Aranda Richard · Chief Medical Officer | Common Stock | S — Open market or private sale | −1,908 | 0.66 | SEC filing |
| 2024-06-21 | Hasnain Faheem · President & CEO | Common Stock | P — Open market or private purchase | +372,000 | 0.67 | SEC filing |
| 2024-06-18 | Giraudo Bryan · COO/CFO | Common Stock | P — Open market or private purchase | +100,000 | 0.59 | SEC filing |
| 2024-06-17 | Smith Robert Paul JR · Chief Commercial Officer | Common Stock | P — Open market or private purchase | +25,000 | 0.60 | SEC filing |
| 2024-03-27 | Giraudo Bryan · COO/CFO | Common Stock | S — Open market or private sale | −6,430 | 1.16 | SEC filing |
| 2024-03-27 | Hasnain Faheem · President & CEO | Common Stock | S — Open market or private sale | −23,172 | 1.16 | SEC filing |
| 2024-03-27 | Christian Waage · EVP, Tech Ops and Admin | Common Stock | S — Open market or private sale | −6,430 | 1.16 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-04 | Milligan Sandra · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +115,000 | SEC filing |
| 2026-06-04 | Daniel Thomas O · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +115,000 | SEC filing |
| 2026-06-04 | Drynan Skye · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +115,000 | SEC filing |
| 2026-06-04 | Cox Russell J. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +115,000 | SEC filing |
| 2026-06-04 | Quisel John D · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +115,000 | SEC filing |
| 2026-06-04 | Nathan Steven D · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +115,000 | SEC filing |
| 2026-03-19 | Aranda Richard · Chief Medical Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +157,500 | SEC filing |
| 2026-03-19 | Smith Robert Paul JR · Chief Commercial Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +572,000 | SEC filing |
Showing 8 of 10 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-03-19 | Smith Robert Paul JR · Chief Commercial Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −572,000 | SEC filing |
| 2026-03-19 | Hasnain Faheem · President & CEO | Stock Option (Right to Buy) | D — Disposition to the issuer | −1,680,000 | SEC filing |
| 2026-03-19 | Christian Waage · EVP, Tech Ops and Admin | Stock Option (Right to Buy) | D — Disposition to the issuer | −440,000 | SEC filing |
| 2026-03-19 | Peterson Caryn · EVP, Regulatory Affairs | Stock Option (Right to Buy) | D — Disposition to the issuer | −9,167 | SEC filing |
| 2026-03-19 | Peterson Caryn · EVP, Regulatory Affairs | Stock Option (Right to Buy) | D — Disposition to the issuer | −32,334 | SEC filing |
| 2026-03-19 | Hasnain Faheem · President & CEO | Stock Option (Right to Buy) | D — Disposition to the issuer | −544,500 | SEC filing |
| 2026-03-19 | Peterson Caryn · EVP, Regulatory Affairs | Stock Option (Right to Buy) | D — Disposition to the issuer | −375,000 | SEC filing |
| 2026-03-19 | Aranda Richard · Chief Medical Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −40,000 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.